Kornimate/medical-research-clean huggingface dataset:
therapeutic anticoagulation strategy for acute chest syndrome

Conditions: Anemia; Sickle Cell; Acute Chest Syndrome; Low-Molecular-Weight Heparin

Summary: acute chest syndrome (acs) is a pulmonary complication of sickle cell disease (scd) representing the leading cause of death and the second cause of hospitalization among adult patients. pulmonary vaso-occlusion is one of the main pathophysiologic hypotheses during acs. our hypothesis is that therapeutic anticoagulation may reduce the severity of acs via the alleviation of pulmonary thrombosis. the main objective of this prospective, randomized, double-blind study is to test the efficacy and safety of a curative anticoagulation strategy during acs. the main efficacy endpoint is time to acs resolution. the main safety endpoint is number of major bleedings. a thoracic ct scan will be performed to check for pulmonary artery thrombosis. if the ct scan is positive (thrombosis within a large elastic artery), the patient will not be randomized and will be treated with a curative anticoagulation. if the ct scan is negative, the patient will be randomized to receive subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) either at a curative dose (175 unit international (ui)/kg/day for 7 days) or at a prophylactic dose (4500 ui/day).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * major sickle cell syndrome (ss, sc, sβ) * acs defined by the association of a new infiltrate on chest x-ray or ct scan and a respiratory symptom or abnormal chest auscultation * written, informed consent main exclusion criteria: * pregnancy, post-partum * iodine allergy * extreme weight (\ 100 kg) * moderate to severe renal insufficiency * moya-moya disease * symptomatic cerebral aneurysm * major transfusional risk * uncontrolled severe retinopathy * all other contra-indications to curative anti-coagulation by tinzaparin.

Keywords: sickle cell disease anemia rare disease reanimation prophylactic anticoagulation
assessment and treat neglect patients with a vr application

Conditions: Neglect, Hemispatial; Stroke; Virtual Reality Therapy

Summary: the objective of this project is to investigate the effectiveness of neglect training in our self-developed vr application "spatialsense". the investigators aim to reach the following goals: i. compare conventional neglect therapy for neglect training with spatialsense to evaluate the impacts on neglect recovery to see whether the vr therapy improves the clinical outcomes, such as balance recovery, perception of verticality, quality of life, independence in daily activities, and cognitive impairment, after rehabilitation training. ii. analyze and compare the search strategies employed by stroke patients with vsn and those without vsn during the execution of the search task with spatialsense to summarize typical visual scanning strategies for facilitation, rehabilitation training, and improving the transfer effect in daily activities. the experimental group will receive both conventional ot and pt treatment, but 3 days a week, half an hour of conventional treatment will be replaced by treatment with spatialsense software. the control group will receive their regular dose-matched conventional ot and pt sessions without interference. the experimental group will receive spatialsense training 3 times a week for a consecutive 4 weeks (12 sessions in total of 30 minutes).

technical information: our vr application is made with the game engine unity (version 2020.2.5f1). we built this for the hmd pico 4 enterprise, which has six degrees of freedom, a 4k rgb display, a 101-degree field of view, and built-in eye-tracking hardware and software. the virtual environment is a 3-dimensional immersive environment in which the participant will be placed in three different virtual scenes: a picnic table, a kitchen, and a playground. this allows for the placement of stimuli in three different regions: near peripersonal (reaching) space, far peripersonal space, and extrapersonal (far) space. the goal of the game is to search for items that appear in front of the view, as accurately and quickly as possible.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. able to provide informed consent 3. have had a hemispheric stroke exclusion criteria: 1. have a severe comorbid psychiatric (e.g. psychotic symptoms) disorder 2. have a premorbid neurodegenerative disease (e.g. alzheimer's dementia, vascular dementia) 3. have severe written language comprehension deficits 4. have a medical implant, such as a cochlear implant or a pacemaker 5. have a severe visual impairment that cannot be corrected by wearing glasses while training 6. have a history of epileptic seizures the following exclusion criteria do not apply to the non-vsn stroke group. 7. do not show signs of a spatial asymmetry in performance on a battery of screening tasks 8. having visual field deficits or lesions in the occipital lobe
operative plate fixation versus conservative treatment for acute, displaced fractures of humeral shaft

Conditions: Humeral Fractures

Summary: conservative treatment versus operative plate fixation for acute, displaced fractures of the distal clavicle

from jane 2015 to october 2016, patients with displaced humeral shaft fractures are retrospectively included in this study, they were treated with either operative plate or conservative treatment. all the patients are regularly followed up in clinic. then we will compare the union rate and clinical functional outcome(dash score) between the 2 groups at 1 year after surgery.

Eligibility criteria:
inclusion criteria: men or women aged 18 to 65 years of age completely displaced ,closed fracture of humeral shaft confirmed by radiograph fractures within 1 month post injury provision of informed consent exclusion criteria: pathological fractures non-displaced (cortical contact) fractures open fractures presence of vascular or nerve injury fractures more than 1 month post-injury limited life expectancy due to significant medical co-morbidity medical contraindication to surgery inability to comply with rehabilitation or form completion likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, patients not mentally competent to give consent, etc.)

Keywords: humeral fractures plate conservative treatment
effects of amlodipine/benazepril on albuminuria in hypertensive patients with type 2 diabetes mellitus

Conditions: Albuminuria

Summary: type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. this study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * mild to moderate hypertension * type 2 diabetes mellitus * presence of protein in the urine (albuminuria) exclusion criteria: * kidney disease not caused by diabetes or hypertension * renal artery stenosis * myocardial infarction or stroke within the last 6 months * type 1 diabetes mellitus * pregnant or lactating females * cancer within the last 5 years

Keywords: albuminuria type 2 diabetes mellitus hypertension
identification of fecal microbiota biomarkers of spondyloarthritis in patients suffering from crohn's disease.

Conditions: Crohn Disease; Spondyloarthritis

Summary: the microspa project aims to compare gut microbiota, serum cytokines, and pbmc of patients suffering from crohn's disease (cd) associated or not to spondylarthritis (spa). 3 groups of patients will be analyzed: patients suffering from cd alone, patients suffering from spa alone, patients suffering from cd and spa. one group of healthy controls will be analysed as a comparator. fecal microbiota will be determined by bacteriome, virome and fungome ngs sequencing


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * patients will be recruited according to 3 groups: * patients with crohn's disease and axial spondyloarthritis according to the criteria below. * patients with crohn's disease (mc patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. with diagnosis of exclusion of a spondyloarthritis on criteria asas and / or new york modified. * patients with axial spondyloarthritis (spa patients) with a diagnosis based on modified asas and / or new york criteria with exclusion diagnosis of crohn's disease. * patient with the ability to give free and express informed consent. exclusion criteria: * history of colonic resection * taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation). * ostomy at the time of sampling * bmi\> 30 * extreme diet * unbalanced diabetes * pregnant woman * patient under guardianship, under curatorship or under the protection of justice contacts/locations central contact
a study to evaluate the single dose safety, tolerability and pharmacokinetics of iv bcx4430

Conditions: Marburg Virus Disease

Summary: this is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by iv infusion

this single ascending dose study will evaluate the safety, tolerability, and pk of single doses of galidesivir vs. placebo administered as iv infusions in healthy subjects enrolled in up to four dose cohorts of 8 subjects each. a single dose of study drug will be administered per cohort: 6 subjects will receive galidesivir iv, and 2 subjects will receive matching placebo.

Eligibility criteria:
key inclusion criteria: * written informed consent * males and non-pregnant, non-lactating females * bmi 19.0-32.0 * willing to abide by contraceptive requirements * normal vitals * willing to abide by study procedures and restrictions exclusion criteria: * clinically significant medical condition or medical history or psychiatric condition or history of psychiatric condition * abnormal cardiac finding, or laboratory/urinalysis abnormality at screening * known family history of sudden death or long qt syndrome, family or personal history of qt prolongation, or arrhythmia that required medical intervention * current participation in any other investigational drug study or participation in an investigational drug study within 3 months of screening visit * use of prescription, otc, or herbal medications during study or use of any specified medications within 30 days prior to study * recent or current history of alcohol or drug abuse * regular use of tobacco or nicotine products * positive serology for hbv, hcv, or hiv * history of severe adverse reaction to or known sensitivity to any drug * pregnant, lactating, or planning to become pregnant within 30 days of the study. male subjects with pregnant female partners are excluded
associated disorders of locomotion and postural control of axial segments in cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: gait abnormalities, which occur in cerebral palsy (cp), are characterized usually by a toe-to-floor or a plantar-to-floor initial contact (equinus gait), followed by an early braking of the tibia's forward progression (during ankle dorsiflexion). this causes consequently a trunk deceleration. moreover, children with cp have difficulties to stabilize the trunk and the head in the space, and that could have impact on gait. if equinus gait is often attributed to the triceps surae spasticity, recent works suggest rather that this early braking of the dorsiflexion could be a motor adaptation to axial postural control difficulties. this thesis project aims firstly to attest that locomotor disorders are related to these difficulties in the stabilization of the axial body segments in children with cp and, secondly, to show that improving the trunk and head postural control with a specific rehabilitation protocol could reduce the early braking of the dorsiflexion and, consequently, the gait abnormalities observed in cp.


Eligibility criteria:
inclusion criteria: * gross motor function classification system i or ii * no or minimal contracture of the triceps surae * presence of soleus spasticity exclusion criteria: * botulinum toxin injections or surgery in the lower limb respectively in the 6 and 12 months preceding the study * any modification of the physical or orthopaedic therapy within the last two months * minimal hip flexion above 20° in a clinical examination * pain in the lower legs when standing or walking

Keywords: trunk control postural control cerebral palsy rehabilitation axial segments
efficacy and safety of lc51-0255 in subjects with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this is a phase 2, multi center, randomized, placebo controlled parallel group study to evaluate the clinical efficacy and safety of lc51 0255 in subjects with moderately to severely active ulcerative colitis


Eligibility criteria:
inclusion criteria: * aged 18 to 80 years * active uc confirmed by endoscopy * moderately to severely active uc defined as a 3-component mayo clinic score exclusion criteria: * severe extensive colitis * diagnosis of microscopic colitis, ischemic colitis, or infectious colitis * treatment with cyclosporine, tacrolimus, sirolimus, methotrexate, or mycophenolate mofetil within 16 weeks of screening * treatment with a biologic agent (ie, anti tnfs, anti integrins, and anti interleukin 23) within 8 weeks prior to screening endoscopy * any prior exposure to s1p receptor modulators, natalizumab, lymphocyte-depleting therapies (ie, alemtuzumab, anti cd4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)
comparison of body composition & weight change in users of progestin-only contraception during the first year of use

Conditions: Weight Change

Summary: the purpose of this study is to learn if women gain weight using progestin-only methods of contraception and if so, how much. the investigators will look at users of two progestin-only methods: the levonorgestrel-containing intrauterine contraceptive (lng-iuc) and the etonorgestrel (eng) subdermal implant, and compare these users' weight change to that of users of a non-hormonal method, the copper intrauterine device. the primary hypothesis is that eng implant and lng-iuc users' weight and body composition will increase more than the copper-iud users. the investigators will collect body composition data using dual-energy x-ray absorptiometry (dexa), and collect information about diet and activity using validated questionnaires.


Eligibility criteria:
the study has finished enrolling new participants. inclusion criteria: * participants between the ages of 18 and 45 years * participants starting the copper iud or implant through their provider * first study visit must occur within 14 days of method insertion exclusion criteria: * dmpa in the past 16 weeks * pops, lng-iuc, or the implant in the past 4 weeks * thyroid disease * autoimmune disease * diabetes (excluding gestational) * history of eating disorder * currently taking antidepressants for \< 6 months * currently taking antipsychotics * currently taking oral glucocorticoids (steroids, i.e. prednisone) for more than 6 months * currently breastfeeding * less than 6 months post-partum
pilot comparing ctdna idv vs. spv sample in pts undergoing biopsies for hepatobiliary and pancreatic cancers

Conditions: Hepatobiliary Cancer; Pancreatic Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Ampullary Cancer; Pancreatic Carcinoma

Summary: this is a prospective pilot protocol investigating whether ctdna detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.

this is a, prospective single center pilot study to investigate whether ctdna detection can be improved by sampling the cancer draining vein vs. a peripheral vein (current practice). as a secondary endpoint, both ctdna results will be compared with percutaneous biopsy (standard of care).

Eligibility criteria:
inclusion criteria: * 18 years of age or older * have or are undergoing work-up for hepatobiliary and/or pancreatic carcinoma (such as hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, pancreatic carcinoma) * scheduled for an image-guided percutaneous or trans-jugular biopsy of a lesion * must be able to provide a written informed consent exclusion criteria: * patients unable to hold reasonably still on a procedure table or hold their breath during imaging or needle passes * patients with a gross body weight over 375 pounds (upper limit of the ct and angiography tables) * patients with uncorrectable coagulopathy * platelet count \< 30,000/ul * international normalized (inr) \> 1.5 * patients with moderate to severe ascites who cannot undergo trans-jugular biopsy or sufficient drainage * no clear reachable target for percutaneous or trans-jugular biopsy * patient who cannot have a peripheral blood draw for ctdna

Keywords: ctdna circulating tumor dna pancreatic cancer hepatobiliary cancer
study of the effect of fragmin in the treatment of neuroischaemic foot ulcers in diabetic patients

Conditions: Diabetic Foot Ulcer

Summary: the purpose of the study isto see the effect of fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.


Eligibility criteria:
inclusion criteria: * male or female subjects 18 years of age with type 1 or type 2 diabetes. * subjects with peripheral occlusive arterial disease (paod) and a neuropathy disability score (nds) of \>3 exclusion criteria: * subjects who have undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. subjects with an ulcer grading of 0 or 3 and staging of a, b or d according to the university of texas wound classification system. * subjects with a known bleeding disorder or evidence of active bleeding.

Keywords: diabetic foot ulcers neuroischaemic
evaluation of depression and anxiety in chemotherapy patients

Conditions: Oncology Problem

Summary: this study will examine the existence and severity of depression and anxiety in patients undergoing chemotherapy at rumc. patients currently undergoing initial chemotherapy cycle will be compared to patients undergoing a subsequent chemotherapy cycle. data will then be collected using standardized depression and anxiety scales to assess if these comorbidities exist and to what severity level. data already collected for depression and anxiety in patients with chronic, but not cancer, illness will be used as a control. the participants will be screened for signs of psychological distress using three self administered questionnaires: the generalized anxiety disorder 7 item scale (gad7) and patient health questionnaire (phq9). demographic information about the participants, including medical and psychiatric history, will also be gathered from their medical records.

the purpose of the study is to see how common anxiety, depression and distress are in people who are undergoing treatment for cancer. we want to understand how common these issues are in order to better screen for, and treat people suffering from them. past studies have shown that people with anxiety or depression and cancer have worse outcomes, and a study evaluating how common these issues are has not been done. patients presenting for chemotherapy will be identified and approached for participation by members of the research team. the purpose and design of the study will be explained. after informed consent is obtained, the surveys will be administered by the study team. completing surveys will take 20 minuets. relevant demographic information will be collected from the patients emr. recruitment will extend over one year period. those determined to be suffering from anxiety or depression will be given the option of psychiatric follow up or intervention.

Eligibility criteria:
inclusion criteria:1)patients (greater than equal to) 18 years of age 2)patients with a confirmed diagnosis of a solid tumor or hematologic cancer 3)patients who are able to understand the informed consent and read the selfadministered metrics. 4)patients undergoing chemotherapy. - exclusion criteria: * patients unable to give informed consent. * patients with a previous diagnosis of anxiety or depression prior to chemotherapy
impact of cognitive rehab and physical activity on cognition in patients with metastatic brain tumors undergoing rt

Conditions: Metastatic Brain Tumor; Cerebral Metastases

Summary: to determine the feasibility of processes and instruments with an overarching purpose to guide the design of a larger study. to determine the feasibility of individuals with metastatic brain tumor(s) to engage in physical activity(pa) and cognitive rehabilitation (cr) as in an outpatient therapy setting.

rolling recruitment for the study. participants will be randomized into one of three treatment arms. all treatment arms will undergo physical \& cognitive testing prior to whole-brain radiation therapy (wbrt)/stereotactic radiosurgery (srs). arm 3 will receive cognitive rehabilitation intervention sessions prior to, and concurrent with, wbrt/srs. approximately 14 days following wbrt/srs: all arms will undergo physical and cognitive testing, and: arm 1 will begin physical activity intervention. arm 2 will begin physical activity intervention and cognitive intervention. arm 3 will continue with cognitive intervention and begin physical activity intervention. all arms will undergo physical and cognitive testing approximately 2.5 months post wbrt/srs.

Eligibility criteria:
inclusion criteria: * a potential subject must meet all of the following inclusion criteria to be eligible to participate in the study: * ability to understand and the willingness to provide written informed consent * 18 years of age and older * diagnosed with one or more metastatic brain tumor(s) * medical treatment plan includes whole-brain radiation therapy and / or sterotactic radiosurgery exclusion criteria: * a potential subject who meets any of the following exclusion criteria is ineligible to participate in the study. * diagnosis of dementia or unable to grant their own informed consent * prisoner or patient in custody * patient on psychiatric hold * physically unable to participate in the study * the opinion of the treating physician determines it is not medically safe to participate in the study * pre-registration screen of cognition is "severe" or lower.

Keywords: whole-brain radiation therapy sterotactic radiosurgery cognitive rehabilitation physical activity
long term follow up of a cohort of children with tcf2 mutation:evolution of endocrine and renal function

Conditions: Hepatocyte Nuclear Factor 1-beta

Summary: anomalies of renal development are well know for patients treated for mody-5 diabetes due to tcf2 mutation.a recent study confirms the existence of pediatric patients having tcf2 mutation but presenting renal anomalies alone.endocrine and renal evolution of these patients is unknown.the aim of this study is to follow a cohort of patients with tcf2 mutation and initially presenting renal anomalies alone.

biologic analysis and renal ultrasonography once a year. after puberty or before kidney transplantation * abdominal and pelvic mri * intravenous glucose tolerance test

Eligibility criteria:
inclusion criteria: * patients presenting an anomaly of renal development due to tcf2 mutation * age\<18 years old exclusion criteria: * anomaly of renal development without tcf2 mutation * age≥18 years old * parents or patients refusing to participate to the study

Keywords: hnf1b tcf2 mody-5 cakut anomaly of renal development